Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism Proto-oncogene protein c-fli-1 inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationRare Pediatric Disease (US), Fast Track (US), Orphan Drug (US) |
Molecular FormulaC19H15Cl2NO3 |
InChIKeyZWHNLSHDLKIXOG-UHFFFAOYSA-N |
CAS Registry1903783-78-7 |
Start Date12 Mar 2024 |
Sponsor / Collaborator |
Start Date05 Mar 2024 |
Sponsor / Collaborator |
Start Date01 Aug 2016 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Ewing Sarcoma | Phase 2 | CN | 12 Mar 2024 | |
Ewing Sarcoma | Phase 2 | CN | 05 Mar 2024 | |
Refractory Ewing Sarcoma | Phase 1 | US | 01 Aug 2016 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
NCT02657005 (Pubmed) Manual | Phase 1/2 | 85 | TK216+Vincristine | (ilhtekbled) = ebmjpecmme gtxyuysvev (kddhmsmfgp ) View more | Negative | 02 Jul 2024 | |
NCT02657005 (ASCO2021) Manual | Phase 1/2 | 67 | TK216 | (aayivtxbmm) = asgbnvasbc tbjwxhtovl (jecoxjrtaa ) View more | Positive | 28 May 2021 | |
Phase 1 | 32 | (oqxudxiohs) = other AEs of anemia rfsvmmsfcf (ydstyadmwr ) View more | Positive | 20 Sep 2020 | |||
Phase 1 | 85 | buoibjbrsr(phzkdhcoub) = dhrxajxcyk wsghwhfptq (ihazzsxszj, 367 - 506) | - | 01 Jul 2017 |